Peripheral arterial disease (PAD) is highly prevalent in general population. Data on the prevalence of symptomatic PAD in patients with atrial fibrillation (AF) are limited, and the impact of PAD on adverse outcomes in AF patients is controversial. Our aims were: (i) to define the prevalence of symptomatic PAD in European AF patients and describe its associated clinical risk factors and (ii) to establish the relationship of PAD to adverse events in AF, especially all-cause death.
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation / Proietti, Marco; Raparelli, Valeria; Laroche, Cécile; Dan, Georghe Andrei; Janion, Marianna; Popescu, Raluca; Sinagra, Gianfranco; Vijgen, Johan; Boriani, Giuseppe; Maggioni, Aldo P; Tavazzi, Luigi; Lip, Gregory Y. H.. - In: EUROPACE. - ISSN 1099-5129. - 19:9(2017), pp. 1439-1448. [10.1093/europace/euw169]
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation
BORIANI, Giuseppe;
2017
Abstract
Peripheral arterial disease (PAD) is highly prevalent in general population. Data on the prevalence of symptomatic PAD in patients with atrial fibrillation (AF) are limited, and the impact of PAD on adverse outcomes in AF patients is controversial. Our aims were: (i) to define the prevalence of symptomatic PAD in European AF patients and describe its associated clinical risk factors and (ii) to establish the relationship of PAD to adverse events in AF, especially all-cause death.File | Dimensione | Formato | |
---|---|---|---|
euw169.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
472.23 kB
Formato
Adobe PDF
|
472.23 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris